8-K: Nurix Reports Q3 2025 Results, Advances Clinical Pipeline

Nurix Therapeutics announced its third-quarter 2025 financial results, reporting an increased net loss while advancing pivotal trials for bexobrutideg and progressing strategic collaborations.

Summary

• Reported financial results for the fiscal quarter ended August 31, 2025.
• Preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL patients in H2 2025, with plans for potential accelerated approval and a confirmatory randomized control Phase 3 study.
• Presented preclinical data for GS-6791 (NX-0479), an IRAK4 degrader in collaboration with Gilead, showing potent pathway inhibition and efficacy in a dermatitis model at EADV 2025.
• Presented encore Phase 1a data for bexobrutideg in relapsed or refractory CLL patients at SOHO 2025, achieving an 80.9% Objective Response Rate (ORR) among 47 response-evaluable patients.
• Presented encore data for bexobrutideg in relapsed or refractory Waldenström macroglobulinemia (WM) patients at SOHO 2025, achieving an 84.2% ORR in 19 response-evaluable patients.
• Revenue for the three months ended August 31, 2025, was $7.9 million, compared with $12.6 million for the same period in 2024.
• Research and development expenses for the three months ended August 31, 2025, were $86.1 million, compared with $55.5 million for the same period in 2024.
• General and administrative expenses for the three months ended August 31, 2025, were $13.2 million, compared with $11.7 million for the same period in 2024.
• Net loss for the three months ended August 31, 2025, was $86.4 million, or ($1.03) per share, compared with $49.0 million, or ($0.67) per share, for the same period in 2024.
• Cash, cash equivalents and marketable securities were $428.8 million as of August 31, 2025, compared to $609.6 million as of November 30, 2024.

Sentiment

Score: 5

Explanation: While clinical programs show promising progress and the company is well-capitalized, the significant increase in net loss, decrease in revenue, and substantial cash burn rate indicate deteriorating financial performance. The positive clinical updates are offset by these financial headwinds, leading to a neutral-to-slightly negative sentiment.

Positives

• Initiation of pivotal trials for bexobrutideg in relapsed/refractory CLL patients is planned for H2 2025, with a strategy for potential accelerated approval.
• Bexobrutideg showed strong efficacy in Phase 1a data for relapsed/refractory CLL, with an 80.9% Objective Response Rate (ORR) and durable activity across high-risk subgroups.
• Bexobrutideg demonstrated high efficacy in relapsed/refractory Waldenström macroglobulinemia (WM), achieving an 84.2% ORR.
• Preclinical data for GS-6791 (IRAK4 degrader with Gilead) showed potent pathway inhibition and efficacy in a dermatitis model, supporting its potential in inflammatory conditions.
• Continued advancement of autoimmune disease drug pipeline, including GS-6791 in healthy volunteer studies and the STAT6 degrader with Sanofi in IND-enabling studies.
• Well capitalized with cash and marketable securities of $428.8 million as of August 31, 2025.
• Anticipates achieving substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi, and Pfizer.

Negatives

• Net loss significantly increased to $86.4 million in Q3 2025 from $49.0 million in Q3 2024.
• Revenue decreased to $7.9 million in Q3 2025 from $12.6 million in Q3 2024, primarily due to the initial research term for certain Sanofi collaboration drug targets ending.
• Research and development expenses increased substantially to $86.1 million in Q3 2025 from $55.5 million in Q3 2024, driven by clinical and manufacturing costs.
• General and administrative expenses increased to $13.2 million in Q3 2025 from $11.7 million in Q3 2024.
• Cash, cash equivalents, and marketable securities decreased by $180.8 million from $609.6 million as of November 30, 2024, to $428.8 million as of August 31, 2025, indicating a significant cash burn.
• Net loss per share worsened to ($1.03) in Q3 2025 from ($0.67) in Q3 2024.

Risks

• Uncertainty regarding the ability to advance drug candidates, obtain regulatory approval, and commercialize them.
• Uncertainties related to the timing and results of preclinical studies and clinical trials.
• Challenges in funding development activities and achieving development goals.
• Uncertainties related to the timing and receipt of payments from collaboration partners, including milestone payments and royalties.
• Potential impact of global business, political, and macroeconomic conditions, cybersecurity events, banking system instability, and global conflicts on business, clinical trials, financial condition, liquidity, and results of operations.
• Challenges in protecting intellectual property.

Future Outlook

Nurix anticipates initiating pivotal trials for bexobrutideg in relapsed/refractory CLL in the second half of 2025, with plans for both accelerated and full approval studies. The company is also enrolling a Phase 1b cohort for bexobrutideg in CLL and autoimmune hemolytic anemia and conducting healthy volunteer studies to support a potential autoimmune IND in 2026. Zelebrudomide is advancing in a Phase 1a/1b trial, including an expansion cohort for DLBCL and MCL. NX-1607 is undergoing a Phase 1 trial for immuno-oncology indications. Nurix expects to continue achieving substantial research collaboration milestones with Gilead, Sanofi, and Pfizer and plans to provide additional preclinical, clinical, and program updates throughout 2025.

Management Comments

• "Nurix is preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL patients in the fourth quarter of 2025 and we have outlined our plans for potential accelerated approval with a single arm study as well as a confirmatory randomized control Phase 3 study for full approval."
• "We also continue to advance our autoimmune disease drug pipeline, including the IRAK4 degrader with Gilead, GS-6791, which is currently in healthy volunteer studies, and with the STAT6 degrader with Sanofi, which is currently in IND enabling studies."
• "With a strong wholly owned pipeline and world-class partnerships, Nurix is well positioned to establish degrader-based medicines as a new standard of care in both cancer and autoimmune diseases."

Industry Context

Nurix operates in the highly competitive and innovative biopharmaceutical sector, specifically focusing on targeted protein degradation, a cutting-edge approach to drug design. Its pipeline addresses significant unmet medical needs in oncology (CLL, WM, B-cell malignancies, solid tumors) and autoimmune/inflammatory diseases. The collaborations with major pharmaceutical companies like Gilead, Sanofi, and Pfizer validate its platform and strategy, aligning with a broader industry trend of partnerships to de-risk and accelerate drug development, especially in complex areas like targeted degradation. The advancement of BTK degraders and IRAK4 degraders positions Nurix at the forefront of developing next-generation therapies that aim to overcome limitations of existing kinase inhibitors.

Stakeholder Impact

• Shareholders: Potential for future value creation from clinical pipeline advancements, but significant cash burn and increased net loss could lead to concerns about future dilution or financial stability.
• Employees: Continued investment in R&D and clinical trials suggests stable employment and ongoing scientific work.
• Customers/Patients: Progress in clinical trials for bexobrutideg, GS-6791, and other candidates offers hope for new treatment options for cancer and autoimmune diseases.
• Collaboration Partners (Gilead, Sanofi, Pfizer): Continued advancement of partnered programs and anticipated milestone achievements reinforce the value of these collaborations.

Next Steps

• Initiate pivotal trials for bexobrutideg in relapsed/refractory CLL patients in H2 2025.
• Conduct a single-arm study of bexobrutideg for potential accelerated approval in relapsed/refractory CLL.
• Conduct a randomized controlled Phase 3 trial of bexobrutideg for full approval.
• Enroll a Phase 1b cohort for bexobrutideg in CLL and autoimmune hemolytic anemia.
• Conduct Phase 1 healthy volunteer studies to support a potential autoimmune IND for bexobrutideg in 2026.
• Continue dose escalation study for zelebrudomide in Phase 1a/1b trial.
• Continue evaluation of NX-1607 in an ongoing Phase 1 trial.
• Advance the STAT6 degrader, NX-3911, in IND-enabling studies with Sanofi.
• Achieve substantial research collaboration milestones with Gilead, Sanofi, and Pfizer.
• Provide additional preclinical, clinical, and program updates throughout 2025.

Key Dates

Recommendation

While Nurix Therapeutics demonstrates promising clinical progress with bexobrutideg advancing to pivotal trials and positive preclinical data for partnered programs, the financial results for Q3 2025 show a significant increase in net loss, a decrease in revenue, and a substantial cash burn. The company's cash position, while still robust at $428.8 million, has declined considerably. For a seasoned investor, the clinical upside is compelling but is currently overshadowed by the accelerating financial losses and cash consumption, warranting a cautious "hold" position to monitor the execution of pivotal trials and the trajectory of financial performance.

Keywords

Targeted protein degradation, Biopharmaceutical, Clinical-stage, Cancer, Autoimmune diseases, Bexobrutideg, CLL, Waldenström macroglobulinemia, IRAK4 degrader, GS-6791, STAT6 degrader, Zelebrudomide, NX-1607, BTK degrader, CBL-B inhibitor, Gilead, Sanofi, Pfizer, Drug development, Clinical trials, Financial results